Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFAUGP)

Drug Name
ML213 Drug Info
Synonyms ML 213; ML-213
Cross-matching ID
PubChem CID
3111211
ChEBI ID
CHEMBL91537
CAS Number
CAS 489402-47-3
TTD Drug ID
D0XY2M

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Synaptic vesicle cycle -1.64 4.95e-2 63/78 (80.77%) RIMS1;ATP6V0A2;STX1A;...
Th17 cell differentiation -1.65 4.69e-2 95/107 (88.79%) SMAD4;RORC;RARA;...
T cell receptor signaling pathway -1.65 4.66e-2 93/104 (89.42%) MAPK13;CBLB;MAPK9;...
Ferroptosis -1.67 4.29e-2 36/41 (87.8%) CYBB;TFRC;SLC11A2;...
Type I diabetes mellitus -1.67 4.45e-2 38/43 (88.37%) IL1B;INS;HLA-DPB1;...
Endocrine and other factor-regulated calcium reabsorpti... -1.69 4.17e-2 49/53 (92.45%) PRKACG;ATP2B2;ATP1B1;...
Lysosome -1.69 4.42e-2 115/128 (89.84%) SCARB2;CTSW;SMPD1;...
Autoimmune thyroid disease -1.72 3.77e-2 46/53 (86.79%) HLA-DPB1;HLA-DPA1;CGA;...
GABAergic synapse -1.72 3.84e-2 76/89 (85.39%) GNB2;ADCY9;CACNA1S;...
Estrogen signaling pathway -1.75 3.54e-2 119/137 (86.86%) EBAG9;KRT13;CALML5;...
Antigen processing and presentation -1.76 3.40e-2 60/78 (76.92%) TAPBP;HLA-DPB1;KLRC3;...
Phagosome -1.76 3.35e-2 118/152 (77.63%) ATP6V1E1;TAP2;CYBB;...
Th1 and Th2 cell differentiation -1.78 2.80e-2 80/92 (86.96%) JUN;STAT1;PLCG1;...
Glutamatergic synapse -1.78 2.95e-2 97/114 (85.09%) GRM3;PLD1;GRIN2C;...
Allograft rejection -1.80 2.23e-2 32/38 (84.21%) HLA-DPB1;HLA-DPA1;HLA-DOA;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.80 2.18e-2 79/89 (88.76%) HRAS;CD247;EGFR;...
Hematopoietic cell lineage -1.82 1.34e-2 90/99 (90.91%) FLT3;FLT3LG;CD33;...
Toxoplasmosis -1.84 1.34e-2 103/112 (91.96%) LAMA4;HLA-DPB1;MAPK3;...
Leishmaniasis -1.85 1.61e-2 67/77 (87.01%) ELK1;MAPK11;JUN;...
Pertussis -1.85 2.01e-2 64/76 (84.21%) PYCARD;CXCL6;CALML3;...
Rheumatoid arthritis -1.88 2.23e-2 78/93 (83.87%) ATP6V0A2;JUN;TGFB1;...
Graft-versus-host disease -1.90 2.68e-2 32/42 (76.19%) HLA-F;HLA-DRB1;HLA-A;...
Staphylococcus aureus infection -2.09 0.00e+0 72/95 (75.79%) FPR2;HLA-DPA1;FPR3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H